Showing results (1-10 of 8) with videos related to
Sort By:
Pageof 1
British Journal of Clinical Pharmacology|March 29, 2012
Ro 3-4787, a new β-adrenoceptor blocking agent: Studies in normal volunteersJ R Kilborn, P TurnerNeurodegeneration : a Journal for Neurodegenerative Disorders, Neuroprotection, and Neuroregeneration|December 1, 1996
The bridging concept: optimizing dose for phase II/III in Alzheimer's diseaseN R Cutler, J J Sramek, J R KilbornBritish Medical Journal|April 24, 1971
Further observations on the effect of synthetic thyrotropin-releasing hormone in manB J Ormston, J R Kilborn, R Garry, et al.European Journal of Clinical Pharmacology|January 1, 1981
A comparison between propranolol, practolol and betaxolol (SL75212) on the circulatory and metabolic responses to insulin-induced hypoglycaemiaJ Saunders, R Gomeni, J R Kilborn, et al.British Journal of Clinical Pharmacology|November 1, 1980
Blood concentrations and pharmacodynamic effects of betaxolol (SL 75212) a new beta-adrenoceptor antagonist after oral and intravenous administrationS J Warrington, P Turner, J R Kilborn, et al.Diabete & Metabolisme|December 1, 1981
The effect of non-selective and selective beta-1-blockade on the plasma potassium response to hypoglycaemiaJ Saunders, S A Prestwich, A J Avery, et al.British Journal of Clinical Pharmacology|June 1, 1980
Cardiovascular effects of single oral doses of the new beta-adrenoceptor blocking agents betaxolol (SL 75212) in healthy volunteersP J Cadigan, D R London, B L Pentecost, et al.Arzneimittel-Forschung|January 1, 1980
Pharmacokinetics of the new beta-adrenoceptor blocking agent betaxolol (SL 75212) in man after repeated oral administrationG Bianchetti, C Blatrix, R Gomeni, et al.Pageof 1